Promising Safety, Efficacy Results With Uptake of STRIDE for uHCC

A study presented at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium demonstrated that durvalumab plus tremelimumab (single tremelimumab regular interval durvalumab; STRIDE) led to improved safety and efficacy results in patients with unresectable hepatocellular carcinoma (uHCC).

The study, led by David James Pinato, MD, PhD, MRCP, analyzed the data of 59 patients with uHCC who were treated with STRIDE or durvalumab at 5 centers in the United States, Asia, and Europe between February and May 2023.

Dr. Pinato and colleagues monitored overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and treatment-related adverse events (TRAEs).

Of the 59 patients, 33 (55.9%) received first-line therapy, while 26 (44.1%) received second- or further-line treatment. Twenty-four (40.7%) patients were treated with the STRIDE regimen (6 in the first line and 18 in the second or further line). Child Pugh class A was identified in 32 (54.2%) patients, affecting more patients treated with STRIDE than those treated with durvalumab (79.2% vs 37.1%; P=.003).

In 35 (59.3%) patients, the Eastern Cooperative Oncology Group performance status (ECOG-PS) was 0. ECOG-PS was found more often in patients who previously received STRIDE than those who received durvalumab (79.2% vs 47.0%; P=.015).

Median OS was not attained, with a 6-month OS rate of 59.4% after a median follow-up of 3.2 months (95% CI, 2.6-3.8). In the STRIDE group, median OS was not reached, and the 6-month OS rate was 95.8%, while the durvalumab group experienced a median OS of 4.9 months (95% CI, 3.2-4.9).

Median ORR was 16.3% (95% CI, 6.5-33.5), and median PFS was 2.5 months (95% CI, 1.9-3.8). All observed TRAEs were 42.4% (95% CI, 27.4-62.5), while grade 3-4 TRAEs were 10.2% (95% CI, 3.7-22.1).

“Preliminary observational data from DT-real confirm uptake of STRIDE and [durvalumab] across various lines of therapy, with encouraging efficacy and safety outcomes in routine practice,” the researchers concluded.